Farallon Capital Partners Amends Beam Therapeutics Stake

Ticker: BEAM · Form: SC 13G/A · Filed: Feb 12, 2024

Complexity: simple

Sentiment: neutral

Topics: institutional-ownership, amendment, biotechnology

TL;DR

**Farallon Capital Partners just updated their stake in Beam Therapeutics.**

AI Summary

Farallon Capital Partners, L.P. filed an amended SC 13G/A on February 12, 2024, indicating a change in their ownership of Beam Therapeutics Inc. common stock as of December 31, 2023. This filing updates their previous disclosure, showing their current stake in the gene-editing company. This matters to investors because it provides transparency into institutional ownership, which can influence stock price and signal confidence (or lack thereof) in the company's future prospects.

Why It Matters

This filing updates the public on a significant institutional investor's position in Beam Therapeutics, offering insight into their current investment strategy and potential impact on the stock's liquidity.

Risk Assessment

Risk Level: low — This is a routine update on institutional ownership and does not inherently signal a high-risk event for the company.

Analyst Insight

Investors should note this routine update on institutional ownership, but without specific share count changes, it primarily serves as a transparency update rather than a direct buy/sell signal.

Key Players & Entities

FAQ

What type of filing is this document?

This document is an SC 13G/A, which is an amendment to a Schedule 13G filing, as stated in the 'FORM TYPE: SC 13G/A' section and the title 'SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)'.

Who is the subject company whose shares are being reported?

The subject company is Beam Therapeutics Inc., as indicated under 'SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: Beam Therapeutics Inc.'.

Who is the entity that filed this report?

The entity that filed this report is Farallon Capital Partners, L.P., as stated under 'FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: Farallon Capital Partners, L.P.' and 'NAMES OF REPORTING PERSONS Farallon Capital Partners, L.P.'.

What was the date of the event that triggered this filing?

The date of the event which required the filing of this statement was December 31, 2023, as specified under 'Date of Event which Requires Filing of this Statement'.

What is the CUSIP number for the class of securities reported?

The CUSIP number for the Common Stock, par value $0.01 per share, of Beam Therapeutics Inc. is 07373V105, as listed under 'Cusip Number' and '13G CUSIP No. 07373V105'.

Filing Stats: 4,980 words · 20 min read · ~17 pages · Grade level 12.8 · Accepted 2024-02-12 15:38:11

Key Financial Figures

Filing Documents

From the Filing

SC 13G/A 1 beam_13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) * Beam Therapeutics Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 07373V105 (Cusip Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: Rule 13d-1(b) Rule 13d-1(c) Rule 13d-1(d) * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). (Continued on following pages) Page 1 of 34 Pages Exhibit Index Found on Page 34 13G CUSIP No. 07373V105 1 NAMES OF REPORTING PERSONS Farallon Capital Partners, L.P. 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions) (a) [ ] (b) [ X ]** ** The reporting persons making this filing hold an aggregate of 4,105,753 Shares, which is 5.0% of the class of securities. The reporting person on this cover page, however, is a beneficial owner only of the securities reported by it on this cover page. 3 SEC USE ONLY 4 CITIZENSHIP OR PLACE OF ORGANIZATION California NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5 SOLE VOTING POWER -0- 6 SHARED VOTING POWER 542,347 7 SOLE DISPOSITIVE POWER -0- 8 SHARED DISPOSITIVE POWER 542,347 9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 542,347 10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions) [ ] 11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 0.7% 12 TYPE OF REPORTING PERSON (See Instructions) PN Page 2 of 34 Pages 13G CUSIP No. 07373V105 1 NAMES OF REPORTING PERSONS Farallon Capital Institutional Partners, L.P. 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions) (a) [ ] (b) [ X ]** ** The reporting persons making this filing hold an aggregate of 4,105,753 Shares, which is 5.0% of the class of securities. The reporting person on this cover page, however, is a beneficial owner only of the securities reported by it on this cover page. 3 SEC USE ONLY 4 CITIZENSHIP OR PLACE OF ORGANIZATION California NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5 SOLE VOTING POWER -0- 6 SHARED VOTING POWER 270,501 7 SOLE DISPOSITIVE POWER -0- 8 SHARED DISPOSITIVE POWER 270,501 9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 270,501 10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions) [ ] 11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 0.3% 12 TYPE OF REPORTING PERSON (See Instructions) PN Page 3 of 34 Pages 13G CUSIP No. 07373V105 1 NAMES OF REPORTING PERSONS Farallon Capital Institutional Partners II, L.P. 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions) (a) [ ] (b) [ X ]** ** The reporting persons making this filing hold an aggregate of 4,105,753 Shares, which is 5.0% of the class of securities. The reporting person on this cover page, however, is a beneficial owner only of the securities reported by it on this cover page. 3 SEC USE ONLY 4 CITIZENSHIP OR PLACE OF ORGANIZATION California NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5 SOLE VOTING POWER -0- 6 SHARED VOTING POWER 204,598 7 SOLE DISPOSITIVE POWER -0- 8 SHARED DISPOSITIVE POWER 204,598 9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 204,598 10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions) [ ] 11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 0.3% 12 TYPE OF REPORTING PERSON (See Instructions) PN Page 4 of 34 Pages 13G CUSIP No. 07373V105 1 NAMES OF REPORTING PERSONS Farallon Capital Institutional Partners III, L.P. 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions) (a) [ ] (b) [ X ]** ** The reporting persons making this filing hold an aggregate of 4,105,753 Shares, which is 5.0% of the class of securities. The reporting person on this cover page, however, is a beneficial owner only of the securities reported by it on this cover page. 3 SEC USE ONLY 4 CITIZENSHIP OR PLACE OF ORGANIZATION Delaware NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5 SOLE VOTING POWER -0- 6 SHARED VOTING POWER 91,786 7 SOLE DISPOSITIVE POWER -0- 8 SHARED DISPOSITI

View on Read The Filing